https://www.selleckchem.com/pr....oducts/epacadostat-i
The health care and economic burden of venous thromboembolism (VTE) has been evaluated in regard to acute VTE, VTE recurrence, and some VTE complications, such as postthrombotic syndrome, but the cost burden attributed to bleedings is not well understood. To evaluate health care resource utilization and costs associated with major bleeding (M and clinically relevant nonmajor bleeding (CRNM among a large U.S. commercially and Medicare-insured population with VTE. Patients (≥ 18 years of age, continuously insured) with
Like
Comment
Share
